Q-omics provides the consensus-scored MSRB3 profile across patient tissues and cancer cell-line models. MSRB3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MSRB3 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, MSRB3 protein abundance shows 27,886 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight MESO, KICH, and UCEC as cancer lineages where MSRB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MSRB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MSRB3 survival associations across molecular data types. MSRB3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MSRB3 RNA expression–survival associations across cancer types. High MSRB3 expression shows unfavorable associations in MESO, BLCA, KIRP, UVM, CESC and LUSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for MSRB3 RNA expression.
This table summarizes MSRB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MSRB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MSRB3 shows lower tumor expression in KICH, LUAD, BLCA, THCA, COAD and LUSC. The KICH box plot shows higher MSRB3 RNA expression in normal versus tumor tissue (log2 FC = −2.574, t-test p < 0.001).
This table shows molecular features associated with MSRB3 in patient tissues and cancer cell lines. In patient samples, MSRB3 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, MSRB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
